New hope for ALS patients: experimental drug IFB-088 tested in trial
NCT ID NCT05508074
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether adding IFB-088 to standard riluzole treatment is safe and effective for people with bulbar-onset ALS (a form that first affects speech and swallowing). 51 participants received either IFB-088 plus riluzole or a placebo plus riluzole for 6 months. Researchers measured disease progression using functional scales and monitored side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IFB-088 (also called Icerguastat) plus riluzole
What this could lead to
If it works, this could point toward a new treatment option for people with bulbar-onset ALS, potentially slowing disease progression.
What could go wrong
This is an early exploratory trial with only 51 participants, so results may not be conclusive. The drug may show no benefit or cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHM Hôpital La Timone Adultes SCE Maladies Neuromusculaires / SLA
Marseille, 13385, France
-
CHU Bretonneau
Tours, 37044, France
-
CHU de Nantes - Hôpital Laennec
Nantes, 44093, France
-
CHU de Toulouse - Hôpital Pierre-Paul Riquet
Toulouse, 31059, France
-
Centro Clinico NeMO per le Malattie Neuromuscolari
Gussago, 25064, Italy
-
Hôpital Neurologique Pierre Wertheimer
Bron, 69677, France
-
IRCSS Istituto Neurologico Carlo Besta
Milan, 20133, Italy
-
Ospedale Civile Sant'Agostino Estense
Baggiovara, 41126, Italy
-
Sant'Andrea Hospital Unit of Neuromuscular Disorders
Roma, 00189, Italy